Scior TR - Search Results

1

Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors.

Laufer SA, Domeyer DM, Scior TR, Albrecht W, Hauser DR. Laufer SA, et al. Among authors: scior tr. J Med Chem. 2005 Feb 10;48(3):710-22. doi: 10.1021/jm0408767. J Med Chem. 2005. PMID: 15689155

2

Synthesis, biological testing, and binding mode prediction of 6,9-diarylpurin-8-ones as p38 MAP kinase inhibitors.

Hauser DR, Scior T, Domeyer DM, Kammerer B, Laufer SA. Hauser DR, et al. J Med Chem. 2007 May 3;50(9):2060-6. doi: 10.1021/jm061061w. Epub 2007 Apr 6. J Med Chem. 2007. PMID: 17411025

3

Pharmacophore design of p38α MAP kinase inhibitors with either 2,4,5-trisubstituted or 1,2,4,5-tetrasubstituted imidazole scaffold.

Scior T, Domeyer DM, Cuanalo-Contreras K, Laufer SA. Scior T, et al. Curr Med Chem. 2011;18(10):1526-39. doi: 10.2174/092986711795328409. Curr Med Chem. 2011. PMID: 21428890 Review.

4

Are vanadium compounds drugable? Structures and effects of antidiabetic vanadium compounds: a critical review.

Scior T, Guevara-García A, Bernard P, Do QT, Domeyer D, Laufer S. Scior T, et al. Mini Rev Med Chem. 2005 Nov;5(11):995-1008. doi: 10.2174/138955705774575264. Mini Rev Med Chem. 2005. PMID: 16307529 Review.

5

Why Antidiabetic Vanadium Complexes are Not in the Pipeline of "Big Pharma" Drug Research? A Critical Review.

Scior T, Guevara-Garcia JA, Do QT, Bernard P, Laufer S. Scior T, et al. Curr Med Chem. 2016;23(25):2874-2891. doi: 10.2174/0929867323666160321121138. Curr Med Chem. 2016. PMID: 26997154 Free PMC article. Review.

6

Dapsone is not a Pharmacodynamic Lead Compound for its Aryl Derivatives.

Scior T, Abdallah HH, Salvador-Atonal K, Laufer S. Scior T, et al. Curr Comput Aided Drug Des. 2020;16(3):327-339. doi: 10.2174/1573409915666191010104527. Curr Comput Aided Drug Des. 2020. PMID: 32507104

7

Antitubercular isoniazid and drug resistance of Mycobacterium tuberculosis--a review.

Scior T, Meneses Morales I, Garcés Eisele SJ, Domeyer D, Laufer S. Scior T, et al. Arch Pharm (Weinheim). 2002;335(11-12):511-25. doi: 10.1002/ardp.200290005. Arch Pharm (Weinheim). 2002. PMID: 12596216 Review.

8

Interference of boswellic acids with the ligand binding domain of the glucocorticoid receptor.

Scior T, Verhoff M, Gutierrez-Aztatzi I, Ammon HP, Laufer S, Werz O. Scior T, et al. J Chem Inf Model. 2014 Mar 24;54(3):978-86. doi: 10.1021/ci400666a. Epub 2014 Feb 20. J Chem Inf Model. 2014. PMID: 24512031

9

Application of drug repositioning strategy to TOFISOPAM.

Bernard P, Dufresne-Favetta C, Favetta P, Do QT, Himbert F, Zubrzycki S, Scior T, Lugnier C. Bernard P, et al. Curr Med Chem. 2008;15(30):3196-203. doi: 10.2174/092986708786848488. Curr Med Chem. 2008. PMID: 19075663

10

How to recognize and workaround pitfalls in QSAR studies: a critical review.

Scior T, Medina-Franco JL, Do QT, Martínez-Mayorga K, Yunes Rojas JA, Bernard P. Scior T, et al. Curr Med Chem. 2009;16(32):4297-313. doi: 10.2174/092986709789578213. Curr Med Chem. 2009. PMID: 19754417 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

26 results

Search Page

Filters